IGC Pharma, Inc. (IGC)
0.2797
0.00 (0.00%)
USD |
NYAM |
Oct 08, 16:00
0.2854
+0.01
(+2.04%)
After-Hours: 17:05
IGC Pharma Enterprise Value : 29.40M for Oct. 7, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 07, 2026 | 29.40M |
| October 06, 2026 | 29.40M |
| October 05, 2026 | 29.61M |
| October 02, 2026 | 28.88M |
| October 01, 2026 | 28.38M |
| September 30, 2026 | 28.27M |
| September 29, 2026 | 28.12M |
| September 28, 2026 | 28.79M |
| September 25, 2026 | 29.65M |
| September 24, 2026 | 29.52M |
| September 23, 2026 | 30.03M |
| September 22, 2026 | 29.71M |
| September 21, 2026 | 28.79M |
| September 18, 2026 | 29.92M |
| September 17, 2026 | 28.01M |
| September 16, 2026 | 28.59M |
| September 15, 2026 | 28.06M |
| September 14, 2026 | 28.94M |
| September 11, 2026 | 29.26M |
| September 10, 2026 | 29.71M |
| September 09, 2026 | 29.56M |
| September 08, 2026 | 30.42M |
| September 04, 2026 | 31.25M |
| September 03, 2026 | 31.30M |
| September 02, 2026 | 31.03M |
| Date | Value |
|---|---|
| September 01, 2026 | 31.12M |
| August 31, 2026 | 31.37M |
| August 28, 2026 | 32.48M |
| August 27, 2026 | 34.93M |
| August 26, 2026 | 32.24M |
| August 25, 2026 | 31.92M |
| August 24, 2026 | 31.51M |
| August 21, 2026 | 32.27M |
| August 20, 2026 | 29.12M |
| August 19, 2026 | 29.95M |
| August 18, 2026 | 29.86M |
| August 17, 2026 | 29.40M |
| August 14, 2026 | 31.23M |
| August 13, 2026 | 30.84M |
| August 12, 2026 | 30.01M |
| August 11, 2026 | 29.51M |
| August 10, 2026 | 28.12M |
| August 07, 2026 | 27.01M |
| August 06, 2026 | 26.32M |
| August 05, 2026 | 26.54M |
| August 04, 2026 | 26.13M |
| August 03, 2026 | 25.83M |
| July 31, 2026 | 26.23M |
| July 30, 2026 | 26.28M |
| July 29, 2026 | 25.31M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Cocrystal Pharma, Inc. | 13.71M |
| CNBX Pharmaceuticals, Inc. | 1.394M |
| Arvinas, Inc. | -73.22M |
| Fulcrum Therapeutics, Inc. | -33.60M |
| Definium Therapeutics, Inc. | 3.667B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -2.936M |
| Revenue (Quarterly) | 0.265M |
| Total Expenses (Quarterly) | 3.201M |
| EPS Diluted (Quarterly) | -0.0293 |
| Gross Profit Margin (Quarterly) | 2.64% |
| Profit Margin (Quarterly) | -1.11K% |
| Earnings Yield | -29.17% |
| Normalized Earnings Yield | -29.17 |